Quantitative analysis for Eupraxia Pharmaceuticals Inc. (EPRX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (55.0) (grade B). Gem alpha score: 63.0. 27 signals analyzed (23 differentiated alt-data).
EPRX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $7.40 | $7.07 | $7.34 |
| 2026-05-11 | $7.60 | $7.39 | $7.42 |
| 2026-05-21 | $7.27 | $6.44 | $6.94 |
| 2026-06-03 | $6.67 | $6.33 | $6.33 |
| 2026-06-15 | $6.41 | $6.10 | $6.22 |
| 2026-06-26 | $6.70 | $6.31 | $6.60 |
| 2026-07-09 | $7.11 | $6.80 | $6.91 |
| 2026-07-21 | $6.57 | $6.18 | $6.38 |
| 2026-07-31 | $6.74 | $6.15 | $6.40 |
| 2026-08-12 | $6.79 | $6.41 | $6.48 |
| 2026-08-24 | $7.38 | $6.64 | $7.28 |
| 2026-09-03 | $7.63 | $7.35 | $7.50 |
How Eupraxia Pharmaceuticals Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| HITI | High Tide Inc. | $212M | — |
| HELP | Cybin Inc. Common Stock | $217M | — |
| SGMT | Sagimet Biosciences Inc. | $217M | — |
| WHWK | Whitehawk Therapeutics Inc | $209M | — |
View all Health Care stocks by valuation and signals →
Eupraxia Pharmaceuticals Inc. (EPRX) scores Buy (55.0), and the composite conceals a 54-point disagreement between its dimensions. It is strongest on AI Alpha (gem) at 93 and analyst consensus at 82, and weakest on technicals at 39. A stock can carry AI Alpha (gem) that high while technicals sits at 39; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| AI Alpha (gem) | 93 |
| analyst consensus | 82 |
| ML forecast | 77 |
| technicals | 39 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Eupraxia Pharmaceuticals Inc. (EPRX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/EPRX"><img src="https://stoquant.com/badge/EPRX.svg" alt="Eupraxia Pharmaceuticals Inc. (EPRX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.